녹용

Deer antler velvet (Cervus elaphus L.) is a traditional material in oriental medicine, extensively utilized for its anti-aging, antioxidant, and immune-boosting properties. Our prior research revealed that enzyme-derived deer antler velvet extract (YC-1101) stimulated the immune system by activating macrophages and augmenting splenocyte proliferation. In this study, we investigated the effect of YC-1101 on the proliferation, activation, and cytotoxicity of natural killer (NK) cells, emphasizing activation-receptor upregulation, cytokine secretion, and antitumor efficacy. Our findings demonstrated that YC-1101 treatment markedly enhanced NK cell proliferation in a dose-dependent and time-dependent manner by preserving mitochondrial function. NK cells expanded through YC-1101 treatment exhibited a significant increase in surface expression of activating NK receptors, NKG2D, and NKp44. Additionally, levels of immune-related cytokines like tumor necrosis factor-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor were substantially elevated in the YC-1101-treated group compared with control. Notably, NK cell activation induced by YC-1101 intensified cytotoxicity against various cancer cell lines, and combining YC-1101 with immune checkpoint inhibition synergistically enhanced antitumor activity. Collectively, our results indicate that integration of YC-1101 with expanded NK cells could be a promising approach to augment cancer treatment efficacy.

The likelihood of a drug reaction with lamotrigine is increased by dose escalation that is too rapid or drug interactions that increase the concentration of lamotrigine. There is a well-documented interaction between valproic acid and lamotrigine in which lamotrigine levels are increased, subsequently increasing the risk of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. This syndrome is characterized by fever, lymphadenopathy, diffuse maculopapular rash, multivisceral involvement, eosinophilia, and atypical lymphocytes and has a mortality rate of 10-40%. We describe the first case, to our knowledge, of DRESS syndrome that was probably induced by a drug interaction between lamotrigine and ginseng. A 44-year-old white man presented to the emergency department after experiencing a possible seizure. His medical history included two other lifetime events concerning for seizures at ages 14 and 29 years old. After referral to the neurology clinic, he was diagnosed with generalized tonic-clonic seizure disorder, and lamotrigine was started with up-titration according to the drug's package insert to a goal dosage of 150 mg twice/day. The patient had also been taking deer antler velvet and ginseng that he continued during his lamotrigine therapy. On day 43 of therapy, the patient presented to the emergency department with a pruritic rash that had started on his extremities and spread to his torso. He was thought to have experienced a drug reaction to lamotrigine, and the drug was discontinued. Thirteen days later, the patient was admitted from the acute care clinic for inpatient observation due to laboratory abnormalities in the setting of continued rash, headache, and myalgias. His admission laboratory results on that day were remarkable for leukocytosis, with a white blood cell count up to 17.6 × 10(3) /mm(3) , with a prominent eosinophilia of 3.04 × 10(3) /mm(3) ; his liver enzyme levels were also elevated, with an aspartate aminotransferase level of 191 U/L, alanine aminotransferase level 473 U/L, alkaline phosphatase level 465 U/L, and total bilirubin level 1.4 mg/dl. Use of the Drug Interaction Probability Scale indicated that a drug inter

BACKGROUND: Deer velvet (DV) extract, a traditional remedy in Eastern Asian medicine, holds potential as an immune modulator. This study aimed to investigate the effects of enzymatically digested DV extract, YHC-BE-2040 (HENKIV®), on cell-mediated immunity in a randomized controlled trial. METHODS: Healthy adults (N = 120), aged 40 to 70, were randomly assigned to receive either a high-dose (HD) or low-dose (LD) DV extract, or a placebo daily for 8 weeks. The subjects were instructed to orally administer the provided intervention once a day, taking 2 capsules per dose after a meal. RESULTS: Primary efficacy was measured by natural killer-cell activity, revealing a significant increase in both HD and LD groups compared to placebo (P < .05). Notably, a dose-response relationship was observed, with the HD group exhibiting the most substantial improvement. Secondary parameters TNF-α, IFN-γ, IL-2, and IL-6 showed significant increases in IFN-γ for HD and LD groups. Safety analysis revealed that YHC-BE-2040 was well-tolerated, with no serious adverse events. Reported adverse events were mild to moderate and not definitively linked to the intervention. CONCLUSION: This study provides meaningful insights into the potential of YHC-BE-2040 as an immune function modulator. While promising, further research with clinical endpoints, larger sample sizes, and extended study durations is needed to fully understand the mechanisms and long-term effects of this deer antler extract on human immunity. Nevertheless, these findings support the safe and effective use of YHC-BE-2040 as an immune-enhancing dietary supplement in healthy adults.

AIMS: The aim of this systematic review was to evaluate the evidence from RCTs of velvet antler supplements for any condition, using the QUOROM statement as a guiding framework. METHODS: Four electronic databases (PubMed, Medline, Web of Science and Academic search premier, via the bibliographical platform, Endnote) and two review articles were searched for all randomised clinical trials of velvet antler supplements. Retrieved trials were evaluated according to standardised criteria. RESULTS: Seven RCTs were identified as satisfying all inclusion criteria and examined the effectiveness of velvet antler for rheumatoid arthritis (2), osteoarthritis (1), sexual function (1), and sporting performance enhancement (3). Their methodological quality ranged from 3-5, as measured on the Jadad scale. Two RCTs reported some positive effects of velvet antler supplements, but neither were convincing while the remaining five RCTs found no effect of velvet antler supplements. CONCLUSIONS: Claims made for velvet antler supplements do not appear to be based upon rigorous research from human trials, although for osteoarthritis the findings may have some promise.

To examine the effects of elk velvet antler supplementation (EVA) combined with training on resting and exercise-stimulated hormonal response, male (n = 25) and female (n = 21) rowers ingested either EVA (560 mg/d) or placebo (PL) during 10 wk of training. VO(2max), 2000 m rowing time, leg and bench press strength were determined before and after 5 and 10 wk of training. Serum hormone levels were measured prior to and 5 and 60 min after a simulated 2000 m rowing race. VO(2max)and strength increased and 2000 m times decreased similarly (P < 0.05) with training. There was no significant difference between the EVA and PL group for any hormonal response. Testosterone (males only) and growth hormone (both genders) were higher 5 min after the simulated race (P < 0.05) but returned to baseline at 60 min. Cortisol was higher 5 and 60 min compared to rest (both genders) (P < 0.05) and was higher 60 min post-exercise following 5 and 10 wk of training. It appears that 10 wk of EVA supplementation does not significantly improve rowing performance nor alter hormonal responses at rest or after acute exercise than training alone.

To determine the effects of deer antler velvet on maximal aerobic performance and the trainability of muscular strength and endurance, 38 active males were randomly assigned in a double-blind fashion to either deer antler velvet extract (n = 12), powder (n = 13), or placebo groups (n = 13). Subjects were tested prior to beginning supplementation and a 10-week strength program, and immediately post-training. All subjects were measured for circulating levels of testosterone, insulin-like growth factor, erythropoietin, red cell mass, plasma volume, and total blood volume. Additionally, muscular strength, endurance, and VO2max were determined. All groups improved 6 RM strength equivalently (41 +/- 26%, p < .001), but there was a greater increase in isokinetic knee extensor strength (30 +/- 21% vs. 13 +/- 15%, p = .04) and endurance (21 +/- 19% vs. 7 +/- 12%, p = .02) in the powder compared to placebo group. There were no endocrine, red cell mass or VO2max changes in any group. These findings do not support an erythropoetic or aerobic ergogenic effect of deer antler velvet. Further, the inconsistent findings regarding the effects of deer antler velvet powder supplementation on the development of strength suggests that further work is required to test the robustness of the observation that this supplement enhances the strength training response and to ensure this observation is not a type I error.

This article examines the effects of elk velvet antler on joint pain and swelling, patient/physician global assessment of disease activity, functional ability, quality of life, blood levels of C-reactive protein, and adverse events in persons with stage 2 to 3 rheumatoid arthritis experiencing residual symptoms after standard treatment. Patients (N=168) were enrolled in a 6-month randomized, triple-blind, placebo-controlled clinical trial. Instruments included the Arthritis Impact Measurement Scale, the Health Assessment Questionnaire, tender and swollen joint counts, and 100 mm-length visual analogue scales, along with blood tests. There were no significant differences between groups on any measures. The pattern of change of the measures across time points was essentially the same for both groups. Although some patients reported clinical improvements in their symptoms, there were no statistically significant differences between groups. Overall, elk velvet antler does not effectively manage residual symptoms in patients with rheumatoid arthritis.

OBJECTIVE: To provide evidence for an analgesic effect of antler pedicle compression or lidocaine 'ring block' by comparing changes in median and spectral edge frequencies and total electroencephalographic (EEG) power during the application of each technique followed by antler removal. ANIMALS: Twenty-nine 2-year-old red deer (Cervus elaphus) stags weighing 106-131 kg each were used in this study. Stags were carrying immature growing antler suitable for commercial harvest. MATERIALS AND METHODS: Anaesthesia was induced using propofol (8.25 +/- 1.28 mg kg(-1)) and ketamine (2.18 +/- 0.15 mg kg(-1)) and maintained with halothane in oxygen. End-tidal halothane (Fe'HAL), expired CO(2) tension (Pe'CO(2)), SpO(2), EEG, ECG, and direct arterial blood pressures were recorded continuously. Respiratory rate and somatic responses were recorded at specific time points. After stabilization of anaesthesia (Fe'HAL was approximately 0.8%) baseline data were recorded. Stags were randomly allocated to one of three treatment groups; control, local anaesthesia, or compression band. One antler was removed 4 minutes after the application of treatment. Electroencephalographic responses to application of treatment and antler removal were analysed using area under the curve (AUC) analysis. Mean AUC was compared between groups using anova, and when significant differences were found, groups were compared post hoc with two-tailed t-tests. Significance levels were set at p </= 0.05. RESULTS: Median frequency (F(50)) was increased during antler removal in the control group and during both application and antler removal in the compression group. In the lidocaine group, F(50) was decreased during both application and antler removal. Spectral edge frequency (F(95)) was increased during the antler removal period in the control group and during both application and antler removal in the compression group. In the lidocaine group, F(95) was decreased in the application time period. Total EEG power (P(tot)) was decreased in the removal period in the control group. In the compression group, P(tot) was decreased in the removal period. In the lidocaine group, P(tot) was decreased in the application pe

The purpose of this phase II clinical trial was to examine safety of elk velvet antler taken concurrently with rheumatoid arthritis medications and to determine efficacy by dose to enable sample size estimation and dose standardization for a larger study. Forty patients with stage II rheumatoid arthritis were randomly assigned to 1 of 4 arms of 10 patients each. One group received placebo and the other 3 groups received 2, 4, or 6 capsules (215 mg) of elk velvet antler with appropriate placebos to total 6 capsules daily. All subjects continued to take their arthritis medications. Outcome variables were reported adverse events and health status. At 1 month, there were no significant differences between groups in number of adverse events or health status. The greatest improvement was in the 6 elk velvet antler group, the least was in the placebo group. Differences were not statistically significant. It was concluded that elk velvet antler can be taken safely in conjunction with a number of rheumatoid arthritis medications and should be studied further to assess efficacy.